Program
R2R01
Its studies are mostly in Heart Failure · Acute Kidney Injury · Hepatorenal Syndrome, led by River 2 Renal.
Furthest: phase 2, since May 1, 20233 company-led studies, 2 open or runningNext primary completion: Apr 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| River 2 Renal | 32 open or running | phase 2since May 1, 2023 | May 1, 2023 | Apr 1, 2027phase 2 · NCT07625553 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 1, 2023First study: phase 2 study in Hepatorenal SyndromeFirst studyNCT05875948 · 95 planned · United States
- Jan 31, 2024Phase 2 study in Heart FailureNCT06264310 · 33 enrolled · United States
- Apr 24, 2026Phase 2 study in Acute Kidney InjuryNCT07625553 · 430 planned · Italy
Ahead
- Apr 1, 2027Primary completion: phase 2 study in Acute Kidney InjuryNCT07625553
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07625553Acute Kidney Injury · Italy | 2 | Recruiting | Apr 1, 2027 | 430 |
| NCT06264310Heart Failure · United States | 2 | Completed | Nov 4, 2024 | 33 |
| NCT05875948Hepatorenal Syndrome · United States | 2 | Recruiting | Dec 2024 | 95 |
How it is read
Names in the registry
- “R2R01”, 3 entries
Conditions, from the studies’ own filings
- Heart Failure, 1 study
- Acute Kidney Injury, 1 study
- Hepatorenal Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.